A Critical Analysis of Hepatocellular Carcinoma Trials: Perspectives From Patient Experiences
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 500
- 主要终点
- Number of hepatocellular carcinoma study participants who remain in clinical trial until completion.
研究概览
简要总结
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.
The goal is to identify the obstacles and challenges that prevent participation in hepatocellular carcinoma clinical research, as well as the reasons for withdrawal or discontinuation.
Insights gained from this study will ultimately benefit those with hepatocellular carcinoma who may be invited to participate in clinical research in the years to come.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with hepatocellular carcinoma
- •Willing to comply with all study related procedures and assessments
- •Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol
排除标准
- •No documented diagnosis of hepatocellular carcinoma
- •Any serious and/or unstable pre-existing medical disorders
- •Pregnant or lactating woman
结局指标
主要结局
Number of hepatocellular carcinoma study participants who remain in clinical trial until completion.
时间窗: 12 months
Rate of patients who decide to enroll in a hepatocellular carcinoma clinical study.
时间窗: 3 months
次要结局
未报告次要终点